Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study

Abstract Introduction Adalimumab is a monoclonal antibody that is used to treat autoimmune and inflammatory diseases. Biosimilars for adalimumab, including Hyrimoz, have been developed. We aimed to evaluate the effectiveness and adverse effects of Hyrimoz after switching. Methods The cohort consiste...

Full description

Saved in:
Bibliographic Details
Main Authors: W. H. A. van Poecke, N. E. F. Hooi, T. K. Mossel, M. A. W. Hermans, P. L. A. van Daele, E. M. Bunnik, Z. Brkic, L. K. Sels, A. A. H. J. Thiadens, P. M. van Hagen, J. A. M. van Laar, S. M. Rombach
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Immunology
Subjects:
Flare
adverse effects
biosimilar
adalimumab
Hyrimoz
Humira
Online Access:https://doi.org/10.1186/s12865-025-00693-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12865-025-00693-9

Similar Items